Merck & Co., Inc. (MRK) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

21/25

Growth 4 Margin 4 Expansion 5 Platform 4 Financial 4

latest quarter score

Earnings Reports

21
Merck (MRK) Q2 2026: $5.7B Terns Charge Signals Relentless Pipeline Investment, Not Margin Retreat
August 04, 2026
23
Merck (MRK) Q1 2026: Oncology Portfolio Hits $8B, Pipeline and AI Drive Next Decade’s Growth
May 01, 2026
22
Merck (MRK) Q4 2025: Pipeline Opportunity Surges $20B, Signaling Post-Keytruda Growth Ambition
February 03, 2026
24
Merck (MRK) Q3 2025: Pipeline Expands to 80 Phase III Trials, Diversifying $50B Growth Outlook
October 30, 2025
22
Merck (MRK) Q2 2025: $3B Cost Shift Fuels 20+ Pipeline Launches as Keytruda Hill Nears
July 29, 2025
17
Merck (MRK) Q1 2025: Pipeline Expansion and Supply Chain Realignment Anchor Long-Term Growth Strategy
June 10, 2025

Browse all companies